FI972235A0 - Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos - Google Patents

Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos

Info

Publication number
FI972235A0
FI972235A0 FI972235A FI972235A FI972235A0 FI 972235 A0 FI972235 A0 FI 972235A0 FI 972235 A FI972235 A FI 972235A FI 972235 A FI972235 A FI 972235A FI 972235 A0 FI972235 A0 FI 972235A0
Authority
FI
Finland
Prior art keywords
osteoporosis
prevention
treatment
triarylethylene
derivatives
Prior art date
Application number
FI972235A
Other languages
English (en)
Finnish (fi)
Other versions
FI972235A (sv
Inventor
Alan J Bitonti
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,885 external-priority patent/US5691384A/en
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of FI972235A publication Critical patent/FI972235A/sv
Publication of FI972235A0 publication Critical patent/FI972235A0/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI972235A 1994-11-29 1997-05-27 Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos FI972235A0 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34611194A 1994-11-29 1994-11-29
US08/531,885 US5691384A (en) 1994-11-29 1995-10-11 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
PCT/US1995/013873 WO1996016646A1 (en) 1994-11-29 1995-10-27 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
FI972235A FI972235A (sv) 1997-05-27
FI972235A0 true FI972235A0 (sv) 1997-05-27

Family

ID=26994698

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972235A FI972235A0 (sv) 1994-11-29 1997-05-27 Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos

Country Status (12)

Country Link
US (1) US5693674A (sv)
EP (1) EP0794771A1 (sv)
JP (1) JPH10509962A (sv)
CN (1) CN1167437A (sv)
AU (1) AU707290B2 (sv)
CA (1) CA2206422A1 (sv)
FI (1) FI972235A0 (sv)
HU (1) HUT77603A (sv)
IL (1) IL116142A0 (sv)
MX (1) MX9703944A (sv)
NO (1) NO972426L (sv)
WO (1) WO1996016646A1 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
WO2007135547A2 (en) * 2006-05-22 2007-11-29 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
JP6884100B2 (ja) 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
AU2021255723A1 (en) 2020-04-17 2022-12-08 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
US3247252A (en) * 1962-11-14 1966-04-19 Richardson Merrell Inc Beta-dialkylaminoethylamino-triphenylethanols, -ethanes, and -ethenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US4001229A (en) * 1974-04-04 1977-01-04 Mead Johnson & Company Alkanesulfonamido triphenylethylenes
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
JPH06312930A (ja) * 1993-04-30 1994-11-08 Kuraray Co Ltd 骨粗鬆症治療剤
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
PL181304B1 (pl) * 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL

Also Published As

Publication number Publication date
IL116142A0 (en) 1996-01-31
CN1167437A (zh) 1997-12-10
HUT77603A (hu) 1998-06-29
US5693674A (en) 1997-12-02
EP0794771A1 (en) 1997-09-17
AU707290B2 (en) 1999-07-08
FI972235A (sv) 1997-05-27
JPH10509962A (ja) 1998-09-29
CA2206422A1 (en) 1996-06-06
NO972426D0 (no) 1997-05-28
MX9703944A (es) 1998-05-31
NO972426L (no) 1997-07-29
WO1996016646A1 (en) 1996-06-06
AU4196796A (en) 1996-06-19

Similar Documents

Publication Publication Date Title
FI971969A (sv) Kompositioner för behandling av hemorrojder och användningsmetod
FI970918A0 (sv) Föreningar och förfarande för behandling av cancer
FI952926A0 (sv) Förfaranden för behandling och förebyggande av allFörfaranden för behandling och förebyggande av allergies ergies
FI972235A0 (sv) Förfarande för användning av triaryletylenderivat vid behandling och förhindrande av osteoporos
FI952656A0 (fi) Foerfarande och anordning vid pulsmaetning av en person
FI934519A (fi) Foerfarande foer finfoerdelning av inmatat material vid en kvackningsprocess med flytbaeddskatalysator
IT1277461B1 (it) Procedimento e dispositivo per il trattamento di materiali
FI955786A0 (sv) Användning av naturprodukter och liknande syntetiska föreningar vid behandling av kardiovakulära sjukdomar
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
FI964113A0 (sv) Medicinsk sammansättning för behandling av tardiv dyskinesi och användning av densamma
FI973367A (sv) F"rfarande och anordning f"r behandling av problemavfall
FI934950A0 (fi) Anvaendning av furankarboxamider vid skyddande av material
GB9219776D0 (en) New compounds for use in the treatment of cancer
FI98250B (sv) Anordning och förfarande vid behandling av returflaskor
NO942686D0 (no) Anvendelse av 3-arylindol- og 3-arylindazolderivater ved behandling av psykoser
EP0502470A3 (en) Compounds for the treatment of inflammation and allergy
FI972637A (sv) Användning av K-gruppens vitamin vid behandling av hyperparatyreoidism
FI943518A0 (sv) Förfarande vid rengöring av gasartade ämnen och anordning för att användas vid förfarandet
FI942139A (sv) Mellanprodukter användbara vid framställning av pyranylcyanguanidinderivat och förfarande för framställning av dessa
SE9301084L (sv) Anordning för avstockning och avdragning av sättsand vid plattsättning
FI981527A0 (sv) Anordning och förfarande vid behandling av returflaskor
SE9203342D0 (sv) Anordning vid kontinuerlig passage av vid ytbehandling